not used title
not used title
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Steffen Lang, Ph.D., Global Head of Novartis Technical Operations to discuss how Novartis has plans in place to help ensure their supply chains remain operational even in unexpected situations like COVID-19.
In a situation as the current pandemic, you are racing against time. With events unfolding at speed in the height of a crisis, proactivity and planning — conducted well in advance — are crucial. Last minute changes are more likely to cause disruptions, making matters worse. In fact, big changes in the sourcing of ingredients or the structure of a supply chain cannot happen with the flip of a switch. For this reason, Novartis Technical Operations (NTO), the global manufacturing and supply network of Novartis, has long had in place a business continuity and supply risk management framework to prepare for unexpected situations like COVID-19.
At the first warning signs that the virus would have global ramifications, our framework helped us react swiftly to safeguard the health and wellbeing of our organization’s people, as well as maintain robust inventory levels to ensure our patients would continue to receive the medicines they rely on through the crisis.
Ultimately, five factors have been key to our success so far:
Supply readiness: At the heart of our COVID-19 response was an NTO taskforce that tracked real-time information to examine product supply, internal and external dependencies, risk management and other important data. In addition to maintaining close interaction with suppliers, this knowledge base helped forecast demand, ensure adequate levels of raw materials, plan for potential COVID-19 treatments and Intensive Care Unit (ICU) medicines, and provide an uninterrupted supply to patients.
This ability to react continuously was built on a strong foundation of investment into our supply chain. We are constantly looking for ways to improve our supply readiness with the goal of steadily becoming faster, more agile and at the same time more efficient. Implementing each change is a long process that must be done carefully to avoid disruption. For example, prior to the pandemic, Novartis was midway through a program to link our production sites to create fully integrated and automated, end-to-end supply chain planning.
Supply diversity: Companies with a diverse global footprint can leverage best practice sharing between different locations — including factories, offices, labs, etc. — to accelerate learning. For example, our teams in the countries first impacted by the pandemic, were sharing updates about the pandemic and their response with our colleagues in other parts of the world, which went a long way in preparing these colleagues to respond appropriately when the pandemic reached their region. Additionally, geographic diversity allows Novartis to maintain “dual supply points,” which provided vital flexibility throughout the entire value chain.
Digital readiness: I firmly believe that the more an organization can optimize and go digital, the less vulnerable it will be. Novartis has long placed emphasis on strong digital capabilities, including efforts to simplify and digitize the demand planning process by using predictive analytics and artificial intelligence to generate forecasts. Moreover, our digital readiness and IT infrastructure enabled all our office-based colleagues to immediately switch to work from home at the first warning signs of the pandemic.
Collaboration with health authorities: Close alignment with governmental bodies and health authorities is key to managing any crisis, and in particular the current pandemic where stockpiling behavior was observed in certain markets. By maintaining constant alignment with health authorities and agencies to ensure correct demand and supply balance, we helped reduce or avoid stockpiling behaviors whenever detected, ensuring uninterrupted supply to patients worldwide.
Supporting our people: None of this would have been possible without the incredible efforts of our people, and supporting and empowering them throughout the crisis has been our priority. As well as putting in place measures to keep employees safe – particularly those 
whose continued presence on site is critical to our operations – and introducing more flexible working, we also sought to give our sites the freedom to decide how best to adapt to the new circumstances to maintain production and supply. This enabled an extraordinary level of collaboration between and within sites, as employees adapted working patterns to support and take care of one another, and sites worked collectively to overcome the individual challenges they faced. While the pandemic put an immediate end to travel and much of the face to face interaction to which our teams are accustomed, in many ways it brought our people closer together, and engendered a new level of cohesion across our network.
Nobody wished for this experience, but we’ve taken it as an opportunity to accelerate digitization, to continue strengthening our monitoring and tracking infrastructure, and to introduce new, more flexible ways of working. As we look ahead, we are committed to reimagining medicine and having a positive impact on peoples’ lives now and in the years to come.
Images courtesy: Novartis
Guest Contributor
The PhRMA blog welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view on issues facing our industry and the health care system.
Guest Contributor
Staffing up: Building the future biopharma workforce to keep America in the lead
June 29, 2026
Nearly 80 researchers advocate on Capitol Hill
June 11, 2026
Congratulations to our 2026 Working for Cures Employee Champions
January 29, 2026
Manufacturing U.S. jobs and breakthroughs
October 6, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
Bringing to life the full story of biopharmaceutical innovation and investments
July 22, 2025
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
April 30, 2025
From sound to science: How IP powers innovation in music and hearing
April 25, 2025
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
December 12, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer
January 30, 2024
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
January 29, 2024
Congratulations to our 2023 Working for Cures Employee Champions
December 6, 2023
Watch: Putting patients front and center for World AIDS Day
November 30, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
What you should know about protecting your health this fall
October 16, 2023
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
September 12, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023
Key considerations as Congress works towards PAHPA reauthorization
July 12, 2023
New report shows high-impact R&D happens after cancer medicines are first approved
July 10, 2023
A conversation with Dr. Mike Ybarra on the current state of COVID-19
June 27, 2023
More than 60 researchers ask Congress to support innovation
June 26, 2023
New data: America is an API powerhouse
June 16, 2023
Biopharmaceutical science powered by PRIDE
June 16, 2023
Addressing Mental Health: A conversation with Barry Greene, CEO of Sage Therapeutics
May 30, 2023
Biopharmaceutical manufacturing companies continue to expand their economic footprint across the United States
May 24, 2023
World IP Day 2023: Celebrating women leaders in innovation
April 26, 2023
What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary
April 13, 2023
PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement
March 30, 2023
Celebrating the success of the COVID-19 vaccines, and looking to the future
March 27, 2023
PhRMA submits comments to OSTP on enhancing clinical trial diversity
March 21, 2023
What we’ve learned from three years of fighting COVID-19
March 20, 2023
U.S. must address IP and market access barriers abroad to protect American innovation
January 31, 2023
WTAS: Inflation Reduction Act already impacting R&D decisions
January 17, 2023
Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit
December 8, 2022
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
December 1, 2022
Word of the Month: What is TRIPS?
November 29, 2022
TRIPS waiver expansion risks public health
November 14, 2022
Congratulations to our 2022 Working for Cures Employee Champions
November 10, 2022
Expanding the WTO intellectual property waiver will hurt American jobs
November 9, 2022
Word of the Month: Long COVID
October 19, 2022
Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus
October 13, 2022
Partnerships are driving global COVID-19 treatment access
September 22, 2022
The dangers of expanding the TRIPS waiver
September 19, 2022
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
August 16, 2022
An open letter to Congress: Stand with patients and future cures
August 4, 2022
PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021
July 18, 2022
ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies
July 15, 2022
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
July 14, 2022
COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs
July 7, 2022
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
July 6, 2022
Biopharmaceutical researchers to discuss the value of R&D with Congress
June 9, 2022
Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful
May 23, 2022
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
May 13, 2022
ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond
May 9, 2022
A conversation with Barry Greene, CEO of Sage Therapeutics
May 4, 2022
ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19
April 28, 2022
Stephanie Dyson of BMS on reducing health disparities
April 27, 2022
Biopharmaceutical industry drives economic growth in all 50 states
March 14, 2022
New Data: COVID-19 vaccine global production capacity projected to exceed 20 billion doses this year
February 24, 2022
What you need to know about newly authorized COVID-19 antiviral treatments
February 22, 2022
Guest post: Joining forces to combat the COVID-19 mental health crisis
February 17, 2022
Guest Blog: COVID-19 vaccines are the key to keeping kids healthy
February 16, 2022
Protecting U.S. innovation abroad to support economic and pandemic recovery
February 1, 2022
ICYMI: New report demonstrates growing global impact of antimicrobial resistance
January 24, 2022
Navigating the patient experience in the time of COVID-19
December 6, 2021
Global COVID-19 vaccination matters now and for the future
November 29, 2021
Understanding breakthrough COVID-19 infections
November 11, 2021
New report highlights importance of IP-intensive manufacturing industries to the U.S. economy
November 1, 2021
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
October 29, 2021
The important role of antivirals in the fight against COVID-19
October 6, 2021
Understanding Long COVID-19
September 29, 2021
Upcoming graduate student summit will showcase pathways to success within the biopharmaceutical industry
September 28, 2021
Guest Series: PhRMA talks racial and health equity with Lauren Powell, VP US Health Equity and Community Wellness, Takeda
September 27, 2021
Industry leaders discuss the impact of the drug pricing debate
September 23, 2021
A year and a half later: The biopharmaceutical industry remains committed to beating COVID-19
September 8, 2021
The impact of monoclonal antibodies and COVID-19 recovery
September 2, 2021
Recognizing National Immunization Awareness Month
August 31, 2021
Driving further innovation is critical to global vaccine equity
August 24, 2021
Supporting country readiness to boost global vaccine access
August 12, 2021
Ensuring global vaccine equity requires eliminating trade and regulatory barriers
August 5, 2021
Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine
August 4, 2021
Increasing global access to vaccines by optimizing production
July 29, 2021
Guest post: Retired medics return to the field to take on vaccine delivery and disaster relief
July 23, 2021
PhRMA member companies’ R&D investments reach record high of $91.1 billion in 2020
July 22, 2021
Guest Post: A patient’s story of the long-term health impacts of COVID-19
July 21, 2021
Dose sharing as a part of the COVID-19 global vaccine equity strategy
July 20, 2021
Promoting global vaccine equity while protecting innovation
July 15, 2021
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
July 2, 2021
PhRMA awards $75,000 to fund initiatives to reduce health inequities
July 1, 2021
Watch: Building trust and enhancing clinical trial diversity
June 24, 2021
Building a better health care system: A conversation with Mark Reisenauer, President of Astellas US
June 23, 2021
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
June 22, 2021
Americans 12 years of age and older are eligible for COVID-19 vaccines
June 17, 2021
Researchers to shine light on biopharmaceutical R&D with policymakers
June 15, 2021
PhRMA hosts first stakeholder workshop on clinical trial diversity
June 11, 2021
Coming together to fight COVID-19: A conversation with Barry Greene, CEO of Sage Therapeutics
June 9, 2021
A year later: Reflections on the meaning of equity
May 25, 2021
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
May 21, 2021
Supporting India during the devastating coronavirus surge
May 20, 2021
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
May 14, 2021
The Biden Administration allows politics to upend a pragmatic pandemic response
May 14, 2021
PhRMA CAREs Grant request for proposals: Addressing inequities in access to COVID-19 testing, therapeutics and vaccines
May 6, 2021
Ron Busby, Sr., President and CEO of the U.S. Black Chambers, Inc. on improving vaccine confidence in community
May 5, 2021
Reflecting on Mental Health Awareness Month
May 4, 2021
American leadership on innovation policy is essential to global health progress
May 4, 2021
Patient safety is at the heart of COVID-19 vaccine R&D
April 26, 2021
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
April 12, 2021
Diversifying clinical trials and fighting disease requires equity and trust
April 12, 2021
Building confidence in the COVID-19 vaccine through education
March 22, 2021
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
March 8, 2021
Intellectual property is the key to vaccine development, manufacturing and technology sharing
March 5, 2021
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
March 5, 2021
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
February 24, 2021
Fighting variants of COVID-19
February 22, 2021
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
February 22, 2021
Top five issues voters want addressed in the administration’s first 100 days
February 18, 2021
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
February 12, 2021
Lessons learned from COVID-19: The way we develop new medicines is changing
February 10, 2021
Guest post: PhRMA talks racial and health equity with Stephanie Dyson, Head of Office at Biogen
January 28, 2021
Growing trend: Increased vaccine confidence
January 28, 2021
Election insights: Common ground areas to address Americans’ health care concerns
January 26, 2021
Paper finds gaps in health data are a barrier to health equity
January 11, 2021
New research shows hotspots of inequity relate to increased COVID-19 hospitalizations
January 8, 2021
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
December 21, 2020
Election insights: Voter priorities in the states
December 17, 2020
Report highlights biopharmaceutical industry’s commitment to D&I
December 17, 2020
Strengthening a culture dedicated to patients and equity: A conversation with Percival Barretto-Ko, President of Astellas US
December 16, 2020
Insights from the election: Meeting voters where they are on health care
December 15, 2020
Coming together to fight COVID-19: A conversation with Kabir K. Nath, President & CEO of Otsuka North America Pharmaceutical Bu
December 9, 2020
Guest post: How COVID-19 underscores the importance of public confidence in vaccines
December 7, 2020
Guest Post: Bringing our best to the fight against COVID-19
December 3, 2020
An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibb
November 18, 2020
Deep dive: The issues that drove the 2020 vote
November 13, 2020
Understanding the emergency use authorization process for COVID-19 vaccines
November 12, 2020
ICYMI: Addressing health inequities: Biopharmaceutical companies are rising to the occasion
November 2, 2020
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
November 2, 2020
Voters want to address the real drivers of health care costs for patients and the system
November 2, 2020
Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President of Lundbeck
October 28, 2020
Proposed change to Medicaid line extension definition ignores importance of critical improvements in treatments
October 13, 2020
New Report: The biopharmaceutical industry’s sustained commitment to inspiring and advancing tomorrow’s STEM workforce
October 12, 2020
Manufacturing Day 2020: A closer look at the biopharmaceutical industry’s contributions
October 2, 2020
Coming together to fight COVID-19: A conversation with Alexander Hardy, CEO of Genentech
October 1, 2020
Leading researchers to spotlight the critical role of biopharmaceutical R&D
October 1, 2020
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
September 30, 2020
Coming together to fight COVID-19: A conversation with Ramona Sequeira, President of Takeda Pharmaceuticals U.S.A
September 23, 2020
Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.
September 17, 2020
PhRMA member companies invested $83 billion in research and development last year
September 10, 2020
Coming together to fight COVID-19: A conversation with Paul Hudson, CEO of Sanofi
September 2, 2020
Three ways the pharmaceutical industry can positively impact health equity
September 1, 2020
The 2020 We Work for Health Champion Awards showcase the best of our industry
August 27, 2020
Summer reading in the age of COVID-19
August 21, 2020
The patient perspective navigating COVID-19
August 11, 2020
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
August 4, 2020
Executive order threatens R&D when we need it most to fight COVID-19
July 30, 2020
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
July 22, 2020
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
July 21, 2020
New report explores setbacks that bring future cancer success stories
July 16, 2020
By the numbers: A look at the sourcing of API used in medicines consumed in the United States
July 16, 2020
R&D Focus: 5 things to know about the biopharmaceutical research ecosystem
July 13, 2020
PhRMA’s Lori Reilly joined CSG to discuss the industry’s response to COVID-19 and what it means for states
July 13, 2020
New initiative to bridge the gap on antimicrobial innovation
July 9, 2020
Guest Post: Pride started with protest: Combatting the dual pandemics of COVID-19 and racism this Pride Month
June 30, 2020
How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective
June 29, 2020
In combating COVID-19, science is how we get back to normal
June 24, 2020
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
June 24, 2020
Guest post: A post-pandemic crisis: The mental toll on America
June 16, 2020
Guest Post: From lab to jab: Vaccine development to prevent COVID-19
June 11, 2020
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
June 11, 2020
PhRMA awards $100,000 to fund projects that address health inequalities
June 10, 2020
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
June 5, 2020
America’s global leadership in biopharmaceutical manufacturing
June 4, 2020
What scientific experts are saying about vaccine safety
June 4, 2020
Guest Post: Honoring Asian and Pacific Islander heritage in the age of COVID-19
May 29, 2020
IP Explained: Intellectual property system working to combat COVID-19
May 28, 2020
Guest Post: What will we learn from COVID-19?
May 27, 2020
It’s a good thing pharmaceutical manufacturing supply chains are spread out around the world
May 21, 2020
Clinical Trials Awareness Week: Recognizing unsung heroes in medical research
May 18, 2020
Setting up a pharmaceutical manufacturing supply chain is a complex and lengthy process
May 14, 2020
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
May 4, 2020
Guest Post: Preserving clinical research sites during the coronavirus pandemic
April 29, 2020
Observing National Minority Health Month in the age of COVID-19
April 24, 2020
New report shows nearly 260 vaccines in development, including dozens for COVID-19
April 23, 2020
Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines
April 15, 2020
Guest post: Securing the health care supply chain during COVID-19
April 14, 2020
To the millions affected by COVID-19
April 9, 2020
New infographic: How we are fighting COVID-19
April 8, 2020
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
April 6, 2020
The biopharmaceutical industry’s unique role in responding to COVID-19
April 2, 2020